Trevena
TRVN
S$0.32
Share price
0.00%
Change (1 day)
-95.97%
Change (1 year)
Categories
Trevena (TRVN) - P/B ratio
P/B ratio as of July 2025 : -0.0093
According to Trevena's latest financial reports the company has a price-to-book ratio of 0.395507.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Trevena - P/B ratio (from 2014 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | -0.0682 | -95.23% |
| 2023-12-31 | -1.43 | -324.62% |
| 2022-12-31 | 0.6370 | -57.04% |
| 2021-12-31 | 1.48 | -54.93% |
| 2020-12-31 | 3.29 | 24.91% |
| 2019-12-31 | 2.63 | 208.99% |
| 2018-12-31 | 0.8525 | -70.38% |
| 2017-12-31 | 2.88 | -26.5% |
| 2016-12-31 | 3.92 | 5.08% |
| 2015-12-31 | 3.73 | 57.55% |
| 2014-12-31 | 2.37 | |
| 2013-12-31 | N/A | |
| 2012-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | P/B ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 26.3 | -283,947.10% | 🇺🇸 USA |
 Cytokinetics
CYTK | -16.1 | 173,607.68% | 🇺🇸 USA |
 Cara Therapeutics
CARA | -1.77 | 18,960.33% | 🇺🇸 USA |
 Merck MRK | 4.29 | -46,372.29% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | 1.03 | -11,256.53% | 🇺🇸 USA |